Drive Your Non-Small Cell Lung Cancer Therapy Trials in the Right Direction with Worldwide
Non-small cell lung cancers (NSCLC) account for the majority of lung cancers and lung cancer deaths in the world. We know NSCLC can arise as a consequence of smoking, but they also can arise in nonsmokers as a consequence of exposure to secondhand smoke, asbestos, and other environmental hazards. If caught early, individuals with NSCLC have a 60-70% 5-year survival rate; if the cancer is advanced, the 5-year survival rate is less than 1%.
Surgery has long been the primary response to NSCLC, with radiation and chemotherapy treatments supplementing surgery to improve long-term outcomes. More recently, though, researchers have been looking at exciting new approaches to attacking NSCLC, including biologics and immunotherapies that stimulate the body’s own immune system to fight the cancers.
Bringing such novel approaches to market, though, requires stringent clinical testing, and no CRO is better positioned to help shepherd your work through this process than Worldwide Clinical Trials. We have more than 30 years of experience supporting research in oncology, respiratory disorders, immune-mediated inflammatory disorders (IMID), and novel therapy development. We are internationally acclaimed experts in clinical trial management, offering full-service support for Phase I-Phase IV clinical trials. We also offer real-world evidence clinical research services that can help you better understand the short- and long-term effects of the therapies you are working to bring to market.
When you’re ready to take your next step, take that step in stride with Worldwide.